Efocipegtrutide vs retatrutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
Efocipegtrutide
Developed by Hanmi Pharmaceutical
NCT03374241 · Phase 1 · completed
The study was randomized, blinded and placebo-controlled, a solid safety-study design, but its only primary measure was a count of adverse events rather than a clinical or weight-related efficacy outcome, and no statistical test was applied to those counts. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants With Adverse Events (1 month): Number of Participants With Adverse Events (1 month): Cohort 1 Active 3 Participants | Cohort 2 Active 2 Participants | Cohort 3 Active 3 Participants | Cohort 4 Active 7 Participants | Cohort 5 Active 4 Participants | Placebo 7 Participants (not_applicable)
Result source: NCT03374241
retatrutide
Developed by Eli Lilly
NCT05882045 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 1,946 participants enrolled, and its primary endpoint was the clinical obesity outcome of percent change in body weight. The primary comparison favored retatrutide and met its primary endpoint per the sponsor's topline release (no p-value published), but no power calculation or planned enrollment target is provided in the available record, so the evidence is graded moderate rather than strong.
Next expected readout: November 2026 · NCT06662383 (registry estimate)
Reported efficacy
Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80): Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. (met)
Result source: NCT05929079
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Efocipegtrutide | retatrutide |
|---|---|---|
| Body weight, % change | —Not reported | -17.4% vs -1.6%−15.8 vs placeboNCT0488176014 other results
|
| Weight loss of 5% or more | —Not reported | 100% vs 27%+73 vs placeboNCT0488176011 other results
|
| Weight loss of 10% or more | —Not reported | 93% vs 9%+84 vs placeboNCT0488176011 other results
|
| Waist circumference, change (cm) | —Not reported | -19.6 vs -2.6−17 vs placeboNCT0488176011 other results
|
Body weight, % change
- Efocipegtrutide
- —Not reported
- retatrutide
- -17.4% vs -1.6%−15.8 vs placeboNCT04881760
14 other results
- -16.6% vs -1.6% NCT04881760
- -18.3% vs -1.6% NCT04881760
- -12% vs -1.6% NCT04881760
- -13.8% vs -1.6% NCT04881760
- -7.2% vs -1.6% NCT04881760
- -24.2% vs -2.1% NCT04881760
- -21.7% vs -2.1% NCT04881760
- -23.9% vs -2.1% NCT04881760
- -16.3% vs -2.1% NCT04881760
- -17.8% vs -2.1% NCT04881760
- -8.7% vs -2.1% NCT04881760
- -20.8% vs -4% NCT05929079
- -19.1% vs -4% NCT05929079
- -12.7% vs -4% NCT05929079
Weight loss of 5% or more
- Efocipegtrutide
- —Not reported
- retatrutide
- 100% vs 27%+73 vs placeboNCT04881760
11 other results
- 97% vs 26% NCT04881760
- 100% vs 27% NCT04881760
- 100% vs 27% NCT04881760
- 100% vs 26% NCT04881760
- 100% vs 26% NCT04881760
- 87% vs 27% NCT04881760
- 97% vs 27% NCT04881760
- 87% vs 26% NCT04881760
- 94% vs 26% NCT04881760
- 64% vs 27% NCT04881760
- 59% vs 26% NCT04881760
Weight loss of 10% or more
- Efocipegtrutide
- —Not reported
- retatrutide
- 93% vs 9%+84 vs placeboNCT04881760
11 other results
- 90% vs 3% NCT04881760
- 90% vs 9% NCT04881760
- 91% vs 9% NCT04881760
- 83% vs 3% NCT04881760
- 94% vs 3% NCT04881760
- 73% vs 9% NCT04881760
- 76% vs 9% NCT04881760
- 59% vs 3% NCT04881760
- 72% vs 3% NCT04881760
- 27% vs 9% NCT04881760
- 25% vs 3% NCT04881760
Waist circumference, change (cm)
- Efocipegtrutide
- —Not reported
- retatrutide
- -19.6 vs -2.6−17 vs placeboNCT04881760
11 other results
- -14.3 vs -2.6 NCT04881760
- -18.5 vs -2.6 NCT04881760
- -18.5 vs -2.6 NCT04881760
- -13.7 vs -2.6 NCT04881760
- -15.0 vs -2.6 NCT04881760
- -14.6 vs -2.6 NCT04881760
- -14.9 vs -2.6 NCT04881760
- -10.3 vs -2.6 NCT04881760
- -12.6 vs -2.6 NCT04881760
- -6.5 vs -2.6 NCT04881760
- -5.4 vs -2.6 NCT04881760
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Efocipegtrutide: 4 of 5 rows · retatrutide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Efocipegtrutide | retatrutide |
|---|---|---|
| BMI absolute change · kg | 35.74 vs 34.61 placebo kg @ 12wk0.08 mg/kga,b,c,d,e NCT03744182 · Phase 1 · registry result, not featured evidence show 4 more doses40.13 vs 34.61 placebo kg @ 12wk0.06 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 37.86 vs 34.61 placebo kg @ 12wk0.04 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 32.91 vs 34.61 placebo kg @ 12wk0.02 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 35.46 vs 34.61 placebo kg @ 12wk0.01 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence | -9.14 vs -0.72 placebo kg @ 48wk12 mg (2 mg)a,b,c,d,e NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more doses-8.12 vs -0.72 placebo kg @ 48wk8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 -9.02 vs -0.72 placebo kg @ 48wk8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 -6.67 vs -0.72 placebo kg @ 48wk4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 -6.14 vs -0.72 placebo kg @ 48wk4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 -3.22 vs -0.72 placebo kg @ 48wk1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Dropout rate | —Cohort 1 Activef NCT03374241 · Phase 1 show 9 more results—Cohort 2 Active NCT03374241 · Phase 1 —Cohort 3 Active NCT03374241 · Phase 1 —Cohort 4 Active NCT03374241 · Phase 1 —Cohort 5 Active NCT03374241 · Phase 1 11.1%0.08 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 16.7%0.04 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.02 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.01 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence | 12.9%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results14.3%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 17.1%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 23.5%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 21.2%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 13%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Discontinued due to AEs | —Cohort 1 Activef NCT03374241 · Phase 1 show 9 more results—Cohort 2 Active NCT03374241 · Phase 1 —Cohort 3 Active NCT03374241 · Phase 1 —Cohort 4 Active NCT03374241 · Phase 1 —Cohort 5 Active NCT03374241 · Phase 1 —0.08 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.06 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.04 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.02 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence —0.01 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence | 3.2%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results2.9%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 2.9%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 0%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 3%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 1.4%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Serious AEs | 0%Cohort 1 Activef NCT03374241 · Phase 1 show 9 more results0%Cohort 2 Active NCT03374241 · Phase 1 0%Cohort 3 Active NCT03374241 · Phase 1 0%Cohort 4 Active NCT03374241 · Phase 1 0%Cohort 5 Active NCT03374241 · Phase 1 0%0.08 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.06 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.04 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.02 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence 0%0.01 mg/kg NCT03744182 · Phase 1 · registry result, not featured evidence | 3.2%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results2.9%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 5.7%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 6.1%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 0%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4.3%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Most frequent reported AEs | f general disorders and administration 33.3% (placebo 40%) infections and infestations 16.7% (placebo 0%) musculoskeletal and connective tissue 16.7% (placebo 0%) NCT03374241 · Phase 1 show 9 more resultsblood and lymphatic system disorders 16.7% (placebo 0%) general disorders and administration 16.7% (placebo 40%) nervous system disorders 16.7% (placebo 20%) NCT03374241 · Phase 1 musculoskeletal and connective tissue 33.3% (placebo 0%) eye disorders 16.7% (placebo 0%) general disorders and administration 16.7% (placebo 40%) NCT03374241 · Phase 1 gi disorders 57.1% (placebo 10%) nervous system disorders 57.1% (placebo 20%) general disorders and administration 28.6% (placebo 40%) NCT03374241 · Phase 1 gi disorders 66.7% (placebo 10%) infections and infestations 33.3% (placebo 0%) nervous system disorders 33.3% (placebo 20%) NCT03374241 · Phase 1 0.08 mg/kg nausea 33.3% (placebo 5.9%) bone contusion 11.1% (placebo 0%) decreased appetite 11.1% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.06 mg/kg nausea 33.3% (placebo 5.9%) decreased appetite 22.2% (placebo 5.9%) chest pain 11.1% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.04 mg/kg glucose urine present 16.7% (placebo 5.9%) nausea 16.7% (placebo 5.9%) upper respiratory tract infection 16.7% (placebo 17.6%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.02 mg/kg injection site erythema 20% (placebo 0%) animal bite 10% (placebo 0%) decreased appetite 10% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence 0.01 mg/kg upper respiratory tract infection 44.4% (placebo 17.6%) injection site erythema 11.1% (placebo 0%) nausea 11.1% (placebo 5.9%) NCT03744182 · Phase 1 · registry result, not featured evidence | 12 mg (2 mg) nausea 45.2% (placebo 11.4%) decreased appetite 29% (placebo 8.6%) covid-19 24.2% (placebo 20%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results8 mg (2 mg) diarrhoea 20% (placebo 11.4%) covid-19 17.1% (placebo 20%) nausea 17.1% (placebo 11.4%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 8 mg (4 mg) nausea 60% (placebo 11.4%) covid-19 31.4% (placebo 20%) decreased appetite 31.4% (placebo 8.6%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4 mg nausea 36.4% (placebo 11.4%) decreased appetite 24.2% (placebo 8.6%) covid-19 18.2% (placebo 20%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4 mg (2 mg) decreased appetite 18.2% (placebo 8.6%) nausea 18.2% (placebo 11.4%) constipation 15.2% (placebo 2.9%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 1 mg covid-19 18.8% (placebo 20%) nausea 14.5% (placebo 11.4%) decreased appetite 13% (placebo 8.6%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 1.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 48 weeks versus 12 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
retatrutide
show 14 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Efocipegtrutide's landscape · retatrutide's landscape